Synaptogenix discloses positive results of further bryostatin trial analyses in presentation at alzheimer's association international conference 2021

New york, july 26, 2021 /prnewswire/ -- synaptogenix, inc. (nasdaq: snpx), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that its abstract for presentation at the alzheimer's association international conference (aaic) is now available entitled "bryostatin restores cognitive functions above baseline in advanced alzheimer's disease (ad) patients: a regenerative therapeutic strategy." "recent further analyses of pre-specified cohort results revealed clear evidence of bryostatin therapeutic efficacy for advanced ad patients.
SNPX Ratings Summary
SNPX Quant Ranking